Author(s): Bachert C
Recent advances in experimental immunologic approaches to seasonal allergic rhinitis (SAR) have led to a shift in the concepts of its pathogenesis. The conventional view of SAR as a local response to inhaled allergens has largely given way to a new view of this disorder as a systemic condition with local tissue manifestations. This concept, together with an increasing recognition of specific mediators' distinct roles in driving the early- and late-phase allergic responses, has opened multiple lines of therapeutic attack within the allergic cascade. Potent inhibition of inflammatory mediator release at distinct points in this cascade is conferred by desloratadine. In addition to the familiar range of SAR symptoms amenable to antihistamine therapy, desloratadine uniquely attenuates patient ratings of nasal congestion. This novel, nonsedating histamine H1-receptor antagonist is the only once-daily antiallergic product with a consistent decongestant effect that begins within hours of the first morning dose and is sustained for the entire treatment period.
Author(s): Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, et al.
Author(s): Griffin G, Flynn CA
Author(s): Prince AA, Rosenfeld RM, Shin JJ
Author(s): Chimona TS, Panayiotides JG, Papadakis CE, Helidonis ES, Velegrakis GA
Author(s): Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM, et al.
Author(s): McCormick D, Saeed K, Uchida T, Baldwina C, Deskin R, et al.
Author(s): Rosenfeld RM
Author(s): Butler C, van der Voort J
Author(s): Horak F, Stübner P, Zieglmeyer R, Harris AG
Author(s): Lippert U, Moller A, Welker P, Artuc M, Henz BM
Author(s): Rosenfeld RM, Kay D
Author(s): Horak F, Stübner UP, Zieglmayer R, Harris AG
Author(s): Rovers MM, Schilder AG, Zielhuis GA, Rosenfeld RM
Author(s): Bluestone C, Klein J
Author(s): Dennis RG, Whitmire RN, Jackson RT